New Releases from NCBI BookshelfBrexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over.​Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over.

Post Content

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top